WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Novo Nordisk wants to keep its crown leading the weight-loss drugs pack. Despite outlook downgrades and lawsuits, its CFO has a plan | Fortune

“The ultimate defense in our industry is in innovation,” Karsten Munk Knudsen told Fortune in an exclusive interview.

Raccontata datheguardian.comfortune.com

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
fortune.comStai leggendo6 mesi fa

Novo Nordisk wants to keep its crown leading the weight-loss drugs pack. Despite outlook downgrades and…

“The ultimate defense in our industry is in innovation,” Karsten Munk Knudsen told Fortune in an exclusive interview.

originale
theguardian.com6 mesi fa

Ozempic maker Novo Nordisk cuts sales and profit forecasts again

Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in weight-loss drug market

Leggi questa versione → originale

Timeline cronologica

  1. mercoledì 5 novembre 2025·theguardian.com

    Ozempic maker Novo Nordisk cuts sales and profit forecasts again

    Downgrade comes as Danish company continues to lose ground to Mounjaro firm Eli Lilly in weight-loss drug market

  2. giovedì 6 novembre 2025·fortune.com

    Novo Nordisk wants to keep its crown leading the weight-loss drugs pack. Despite outlook downgrades and lawsuits, its CFO has a plan |…

    “The ultimate defense in our industry is in innovation,” Karsten Munk Knudsen told Fortune in an exclusive interview.